Portal hypertension: Difference between revisions
| Line 13: | Line 13: | ||
==Diagnosis== | ==Diagnosis== | ||
'''Patient #1''' | '''Patient #1''' | ||
Revision as of 14:49, 16 April 2013
| Portal hypertension | |
 | |
|---|---|
| The portal vein and its tributaries. |
|
Portal Hypertension Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Portal hypertension On the Web |
|
American Roentgen Ray Society Images of Portal hypertension |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1],Assistant Editor-in-Chief: Soumya Sachdeva
Pathophysiology
Natural History and Complications
Diagnosis
Patient #1
Patient #2: Recanalized umbilican vein
Treatment
Medical management
Treatment with a non-selective beta blocker is often commenced once portal hypertension has been diagnosed, and almost always if there has already been bleeding from esophageal varices. Typically, this is done with either propranolol or nadolol. The addition of a nitrate, such as isosorbide mononitrate, to the beta blocker is more effective than using beta blockers alone and may be the preferred regimen in those people with portal hypertension who have already experienced variceal bleeding. In acute or severe complications of the hypertension, such as bleeding varices, intravenous octreotide (a somatostatin analogue) or intravenous terlipressin (an antidiuretic hormone analogue) is commenced to decrease the portal pressure.
Percutaneous interventions
Transjugular intrahepatic portosystemic shunting is the creation of a connection between the portal and the venous system. As the pressure over the venous system is lower than over a hypertensive portal system, this would decrease the pressure over the portal system and a decreased risk of complications.
Surgical interventions
The most definitive treatment of portal hypertension is a liver transplant.
References
External links
Template:Gastroenterology de:Portale Hypertension sv:Portahypertension